PTK2 and hepatocellular carcinoma: These cereblon-based compounds degraded FAK with a DC50 of about 30 nM on a panel of eleven HCC cell lines, but, unfortunately, despite their good action on FAK depletion, both were not able to block proliferation of the selected cancer cell lines.